Literature DB >> 22977515

Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks.

Norihiko Suzuki1, Fumio Nakagawa, Mamoru Nukatsuka, Masakazu Fukushima.   

Abstract

TAS-102 is an oral anticancer drug composed of trifluorothymidine (TFT) and TPI (an inhibitor of thymidine phosphorylase that strongly inhibits the biodegradation of TFT). Similar to 5-fluorouracil (5FU) and 5-fluoro-2'-deoxyuridine (FdUrd), TFT also inhibits thymidylate synthase (TS), a rate-limiting enzyme of DNA biosynthesis, and is incorporated into DNA. TFT exhibits an anticancer effect on colorectal cancer cells that have acquired 5FU and/or FdUrd resistance as a result of the overexpression of TS. Therefore, we examined the mode of action of TFT-induced DNA damage after its incorporation into DNA. When HeLa cells were treated with TFT, the number of ring-open aldehyde forms at apurinic/apyrimidinic sites increased in a dose-dependent manner, although we previously reported that no detectable excisions of TFT paired to adenine were observed using uracil DNA glycosylases, thymine DNA glycosylase or methyl-CpG binding domain 4 and HeLa whole cell extracts. To investigate the functional mechanism of TFT-induced DNA damage, we measured the phosphorylation of ATR, ATM, BRCA2, chk1 and chk2 in nuclear extracts of HeLa cells after 0, 24, 48 or 72 h of exposure to an IC(50) concentration of TFT, FdUrd or 5FU using Western blot analysis or an enzyme-linked immunosorbent assay (ELISA). Unlike FdUrd and 5FU, TFT resulted in an earlier phosphorylation of ATR and chk1 proteins after only 24 h of exposure, while phosphorylated ATM, BRCA2 and chk2 proteins were detected after more than 48 h of exposure to TFT. These results suggest that TFT causes single-strand breaks followed by double-strand breaks in the DNA of TFT-treated cells. TFT (as TAS-102) showed a more potent antitumor activity than oral 5FU on CO-3 colon cancer xenografts in mice, and such antitumor potency was supported by the increased number of double-strand breaks occurring after single-strand breaks in the DNA of the TFT-treated tumors. These results suggest that TFT causes single-strand breaks after its incorporation into DNA followed by double-strand breaks, resulting in DNA damage. This effect of TFT on DNA may explain its potent anticancer activity in cancer therapy.

Entities:  

Year:  2011        PMID: 22977515      PMCID: PMC3440718          DOI: 10.3892/etm.2011.244

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  24 in total

1.  Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance.

Authors:  Eric J Brown; David Baltimore
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

2.  The controlling role of ATM in homologous recombinational repair of DNA damage.

Authors:  C Morrison; E Sonoda; N Takao; A Shinohara; K Yamamoto; S Takeda
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

Review 3.  Regulation of DNA repair throughout the cell cycle.

Authors:  Dana Branzei; Marco Foiani
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02-20       Impact factor: 94.444

4.  Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.

Authors:  H H Backus; H M Pinedo; D Wouters; C M Kuiper; G Jansen; C J van Groeningen; G J Peters
Journal:  Oncol Res       Date:  2000       Impact factor: 5.574

5.  Effects of 5-trifluoromethyldeoxyuridine upon deoxythymidine kinase.

Authors:  E Bresnick; S S Williams
Journal:  Biochem Pharmacol       Date:  1967-03       Impact factor: 5.858

6.  Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: its mechanism of action and inhibition by fluorinated nucleotides.

Authors:  P Reyes; C Heidelberger
Journal:  Mol Pharmacol       Date:  1965-07       Impact factor: 4.436

7.  Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells.

Authors:  Y Murakami; H Kazuno; T Emura; H Tsujimoto; N Suzuki; M Fukushima
Journal:  Int J Oncol       Date:  2000-08       Impact factor: 5.650

8.  Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells.

Authors:  D A Greenhalgh; J H Parish
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Simple and rapid enzymatic method for the synthesis of single-strand oligonucleotides containing trifluorothymidine.

Authors:  Norihiko Suzuki; Masakazu Fukushima
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2010-11       Impact factor: 1.381

10.  ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2.

Authors:  Andrea Beucher; Julie Birraux; Leopoldine Tchouandong; Olivia Barton; Atsushi Shibata; Sandro Conrad; Aaron A Goodarzi; Andrea Krempler; Penny A Jeggo; Markus Löbrich
Journal:  EMBO J       Date:  2009-09-24       Impact factor: 11.598

View more
  17 in total

1.  Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells.

Authors:  Paola Orlandi; Daniela Gentile; Marta Banchi; Federico Cucchiara; Teresa Di Desidero; Chiara Cremolini; Roberto Moretto; Alfredo Falcone; Guido Bocci
Journal:  Invest New Drugs       Date:  2019-06-01       Impact factor: 3.850

2.  Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells.

Authors:  Ashley A Untereiner; Athanasia Pavlidou; Nadiya Druzhyna; Andreas Papapetropoulos; Mark R Hellmich; Csaba Szabo
Journal:  Biochem Pharmacol       Date:  2017-10-20       Impact factor: 5.858

3.  Re-evaluation of the Mutagenic Response to Phosphorothioate Nucleotides in Human Lymphoblastoid TK6 Cells.

Authors:  Amer F Saleh; Catherine C Priestley; Nigel J Gooderham; Mick D Fellows
Journal:  Toxicol Sci       Date:  2015-02-20       Impact factor: 4.849

4.  Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.

Authors:  M Suenaga; M Schirripa; S Cao; W Zhang; D Yang; S Murgioni; D Rossini; F Marmorino; A Mennitto; Y Ning; S Okazaki; M D Berger; Y Miyamoto; R Gopez; A Barzi; T Yamaguchi; F Loupakis; H-J Lenz
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

Review 5.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

6.  Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells.

Authors:  Norihiko Suzuki; Hiroshi Tsukihara; Fumio Nakagawa; Takashi Kobunai; Teiji Takechi
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

7.  Trifluridine selectively inhibits cell growth and induces cell apoptosis of triple-negative breast cancer.

Authors:  Juan Li; Jie Liu; Riqi Wang; He Chen; Cui Li; Minggang Zhao; Fang He; Yaochun Wang; Peijun Liu
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

8.  Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.

Authors:  Mitsukuni Suenaga; Marta Schirripa; Shu Cao; Wu Zhang; Dongyun Yang; Vincenzo Dadduzio; Lisa Salvatore; Beatrice Borelli; Filippo Pietrantonio; Yan Ning; Satoshi Okazaki; Martin D Berger; Yuji Miyamoto; Roel Gopez; Afsaneh Barzi; Toshiharu Yamaguchi; Fotios Loupakis; Heinz-Josef Lenz
Journal:  Eur J Cancer       Date:  2017-10-06       Impact factor: 9.162

Review 9.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

Review 10.  Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Authors:  Lars Petter Jordheim; David Durantel; Fabien Zoulim; Charles Dumontet
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.